Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CXCR4 Antibody

Goat Polyclonal Antibody has been used in 3 publications
Supplier: Novus Biologicals NB100716
Description
CXCR4 Polyclonal specifically detects CXCR4 in Human, Rat samples. It is validated for Western Blot, ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
CXCR4 | |
Polyclonal | |
Unconjugated | |
10mM KHPO4, 0.14M NaCl and 1.0 mg/ml BSA with 0.1% Sodium Azide | |
CD184, chemokine (C-X-C motif) receptor 4, chemokine (C-X-C motif), receptor 4 (fusin), C-X-C chemokine receptor type 4, CXC-R4, CXCR-4, D2S201ESDF-1 receptor, FB22, Fusin, HM89NPYRL, HSY3RR, LAP3, LCR1, LESTRCD184 antigen, Leukocyte-derived seven transmembrane domain receptor, leukocyte-derived seven-transmembrane-domain receptor, lipopolysaccharide-associated protein 3, neuropeptide Y receptor Y3, NPY3RWHIM, NPYR, NPYY3R, pCXCR4, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor | |
Goat | |
Affinity Purified | |
RUO | |
Primary | |
Peptide sequence is < 50% identical to other human chemokine receptors in this region | |
Store at -20C. Avoid freeze-thaw cycles. |
Western Blot, ELISA, Immunohistochemistry, Immunohistochemistry (Paraffin) | |
1.0 mg/mL | |
Western Blot 1:250, ELISA 1:25000, Immunohistochemistry 1:150, Immunohistochemistry-Paraffin 1:150 | |
P61073 | |
CXCR4 | |
Synthetic peptide (TEEMGSGDYDSMKEPCFREENANFNKC) corresponding to N-terminal extracellular domain of human CXCR4 receptor. | |
0.1 mg | |
Adaptive Immunity, Cancer, Cytokine Research, GPCR, Growth and Development, Immunology, Innate Immunity, Neuronal Cell Markers, Signal Transduction, Stem Cells | |
7852 | |
Human, Rat | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction